On July 19, 2016, the ACT-AD Coalition hosted a one-hour webinar on clinical meaningfulness in Alzheimer’s disease. The webinar highlighted the history of co-primary outcomes for measuring clinical meaningfulness in overt dementia; explored how thinking on co-primary endpoints is evolving as treatment moves earlier in the disease course; and examined if policy recommendations are necessary for future success in the Alzheimer’s disease clinical trials.
Webinar speakers included:
Cristina Sampaio, M.D., Ph.D.
Chief Clinical Officer
Russell “Rusty” Katz, M.D.
Former Director of the Division of Neurology Products
U.S. Food and Drug Administration
Science Advisory Board Member, Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)
Yaakov Stern, Ph.D.
Professor of Neuropsychology
Taub Institute for the Research on Alzheimer’s Disease and the Aging Brain
Columbia University College of Physicians and Surgeons
Cynthia A. Bens (Moderator)
Vice President of Public Policy, Alliance for Aging Research
Executive Director, Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)